{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:34:50Z","timestamp":1793928890823,"version":"4.8.0"},"reference-count":215,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"HF"},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb","id":[{"id":"https:\/\/ror.org\/00gtmwv55","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.annonc.2019.10.023","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T11:52:01Z","timestamp":1579261921000},"page":"171-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":966,"title":["Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations"],"prefix":"10.1016","volume":"31","author":[{"given":"G.","family":"Curigliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Barac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Blaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lancellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"DeCara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Calabro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Orecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Zamorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Krone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Iakobishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Carver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Armenian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Cipolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2019.10.023_bib1","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMp1113569","article-title":"The burden of disease and the changing task of medicine","volume":"366","author":"Jones","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2010.31.3049","article-title":"Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review","volume":"29","author":"Lee","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0140-6736(13)62225-4","article-title":"Cancer survival: global surveillance will stimulate health policy and improve equity","volume":"383","author":"Coleman","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2019.10.023_bib4","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2012.45.2938","article-title":"Late cardiac effects of cancer treatment","volume":"30","author":"Lenihan","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/annonc\/mdq607","article-title":"Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?","volume":"22","author":"Verma","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annonc.2019.10.023_bib8","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib9","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0140-6736(13)62348-X","article-title":"Statins, risk assessment, and the new American prevention guidelines","volume":"383","author":"Lloyd-Jones","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2019.10.023_bib11","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7326\/M15-0424","article-title":"Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy: A cross-sectional study","volume":"164","author":"Mulrooney","year":"2016","journal-title":"Ann Intern Med"},{"issue":"suppl 7","key":"10.1016\/j.annonc.2019.10.023_bib13","doi-asserted-by":"crossref","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib14","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib15","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1182\/blood-2012-06-437178","article-title":"Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease","volume":"120","author":"Armenian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.023_bib16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31227","article-title":"Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation","volume":"124","author":"Leger","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2013.52.6582","article-title":"Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation","volume":"32","author":"Chow","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib18","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib20","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.annonc.2019.10.023_bib23","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib24","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1200\/JCO.2016.72.0722","article-title":"Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials","volume":"35","author":"Taylor","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib25","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1200\/JCO.2016.71.5581","article-title":"New era in radiation oncology for lung cancer: recognizing the importance of cardiac irradiation","volume":"35","author":"Simone","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib26","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2016.71.6142","article-title":"Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer","volume":"35","author":"Dess","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/eurheartj\/eht114","article-title":"Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease","volume":"35","author":"Groarke","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.annonc.2019.10.023_bib28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jacc.2014.11.035","article-title":"Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes","volume":"65","author":"Groarke","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/clc.22106","article-title":"Frequency of severe valvular disease caused by mediastinal radiation among patients undergoing valve surgery in a community-based, regional academic medical center","volume":"36","author":"Copeland","year":"2013","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0735-1097(03)00759-9","article-title":"Asymptomatic cardiac disease following mediastinal irradiation","volume":"42","author":"Heidenreich","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib31","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","article-title":"Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy","volume":"290","author":"Hull","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2019.10.023_bib32","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib33","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cardfail.2013.07.007","article-title":"Cardiovascular management of cancer patients with chemotherapy-associated left ventricular systolic dysfunction in real-world clinical practice","volume":"19","author":"Ammon","year":"2013","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.annonc.2019.10.023_bib34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12885-016-2761-8","article-title":"Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN)","volume":"16","author":"Pituskin","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib35","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1161\/CIRCULATIONAHA.115.012521","article-title":"Cardiology patient page. ABCDE steps for heart and vascular wellness following a prostate cancer diagnosis","volume":"132","author":"Guan","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.annonc.2019.10.023_bib36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.annonc.2019.10.023_bib37","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.annonc.2019.10.023_bib38","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2019.10.023_bib39","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1161\/01.CIR.96.8.2641","article-title":"Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury","volume":"96","author":"Lipshultz","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.annonc.2019.10.023_bib40","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/annonc\/mdf170","article-title":"Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy","volume":"13","author":"Cardinale","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib41","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/annonc\/mdi152","article-title":"cTnT can be a useful marker for early detection of anthracycline cardiotoxicity","volume":"16","author":"Kilickap","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib42","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib43","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.annonc.2019.10.023_bib44","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib45","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"Zardavas","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib46","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib47","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib48","doi-asserted-by":"crossref","first-page":"e96736","DOI":"10.1371\/journal.pone.0096736","article-title":"BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography","volume":"9","author":"Skovgaard","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2019.10.023_bib49","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib50","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cardfail.2016.04.003","article-title":"The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: A feasibility study","volume":"22","author":"Lenihan","year":"2016","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.annonc.2019.10.023_bib51","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib52","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/annonc\/mds130","article-title":"Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs","volume":"23","author":"Naing","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib53","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ejca.2007.10.001","article-title":"Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development","volume":"44","author":"Curigliano","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib54","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s10637-012-9909-4","article-title":"Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials","volume":"31","author":"Borad","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.annonc.2019.10.023_bib55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11886-016-0730-0","article-title":"Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation","volume":"18","author":"Viganego","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.annonc.2019.10.023_bib56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccep.2015.03.013","article-title":"QT Prolongation and oncology drug development","volume":"7","author":"Fradley","year":"2015","journal-title":"Card Electrophysiol Clin"},{"key":"10.1016\/j.annonc.2019.10.023_bib57","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib58","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","article-title":"Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.annonc.2019.10.023_bib59","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/MJT.0000000000000027","article-title":"Cardiovascular safety monitoring during oncology drug development and therapy","volume":"21","author":"Turner","year":"2014","journal-title":"Am J Ther"},{"key":"10.1016\/j.annonc.2019.10.023_bib60","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.annonc.2019.10.023_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.annonc.2019.10.023_bib62","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib63","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0735-1097(01)01683-7","volume":"38","author":"Hunt","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib64","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1161\/CIRCULATIONAHA.116.023463","article-title":"Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up","volume":"135","author":"Narayan","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.annonc.2019.10.023_bib65","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.annonc.2019.10.023_bib66","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib67","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib68","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u00a0\u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.annonc.2019.10.023_bib69","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib70","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib71","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib72","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.annonc.2019.10.023_bib73","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib74","first-page":"CD003917","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","volume":"1","author":"van Dalen","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.annonc.2019.10.023_bib75","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MPH.0000000000001118","article-title":"Dexrazoxane significantly reduces anthracycline-induced cardiotoxicity in pediatric solid tumor patients: a systematic review","volume":"40","author":"Liesse","year":"2018","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib76","first-page":"1","article-title":"Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series","volume":"5","author":"Ganatra","year":"2019","journal-title":"Cardio-Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature21505","article-title":"Cardiovascular disease: commonality with cancer","volume":"543","author":"Tall","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2019.10.023_bib78","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study","volume":"60","author":"Seicean","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib79","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy","volume":"58","author":"Acar","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib80","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2015.10.008","article-title":"Statins and survival outcomes in patients with metastatic renal cell carcinoma","volume":"52","author":"McKay","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib81","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1200\/JCO.2009.26.7294","article-title":"Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging","volume":"28","author":"Walker","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib82","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib83","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.jacc.2012.01.037","article-title":"Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis","volume":"59","author":"Dorosz","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib84","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1532-429X-15-66","article-title":"Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance","volume":"15","author":"Vasu","year":"2013","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.annonc.2019.10.023_bib85","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jacr.2013.08.018","article-title":"Current opinions on medical radiation: a survey of oncologists regarding radiation exposure and dose reduction in oncology patients","volume":"11","author":"Burke","year":"2014","journal-title":"J\u00a0Am Coll Radiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib86","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1056\/NEJMoa0901249","article-title":"Exposure to low-dose ionizing radiation from medical imaging procedures","volume":"361","author":"Fazel","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib87","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurheartj\/ehi083","article-title":"Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography","volume":"26","author":"Hoffmann","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.annonc.2019.10.023_bib88","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","article-title":"Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity","volume":"26","author":"Negishi","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.annonc.2019.10.023_bib89","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjci\/jet159","article-title":"Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection","volume":"15","author":"Negishi","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.annonc.2019.10.023_bib90","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.annonc.2019.10.023_bib91","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.hlc.2010.09.007","article-title":"The potential role of echocardiographic strain imaging for evaluating cardiotoxicity due to cancer therapy","volume":"20","author":"Stoodley","year":"2011","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.annonc.2019.10.023_bib92","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jcmg.2007.12.007","article-title":"Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: definition of normal range","volume":"2","author":"Marwick","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.annonc.2019.10.023_bib93","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.echo.2003.10.001","article-title":"Noninvasive quantification of regional myocardial function using Doppler-derived velocity, displacement, strain rate, and strain in healthy volunteers: effects of aging","volume":"17","author":"Sun","year":"2004","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.annonc.2019.10.023_bib94","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/oxfordjournals.eurheartj.a015273","article-title":"Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function","volume":"18","author":"Otterstad","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.annonc.2019.10.023_bib95","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1161\/CIRCULATIONAHA.117.027930","article-title":"Early myocardial strain changes during potentially cardiotoxic chemotherapy may occur as a result of reductions in left ventricular end-diastolic volume: The need to interpret left ventricular strain with volumes","volume":"135","author":"Jordan","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.annonc.2019.10.023_bib96","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.amjcard.2017.02.008","article-title":"Frequency of left ventricular end-diastolic volume-mediated declines in ejection fraction in patients receiving potentially cardiotoxic cancer treatment","volume":"119","author":"Melendez","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib97","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib98","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.echo.2008.10.005","article-title":"Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer","volume":"21","author":"Jurcut","year":"2008","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.annonc.2019.10.023_bib99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ejechocard\/jer172","article-title":"Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy","volume":"13","author":"Motoki","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.annonc.2019.10.023_bib100","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.echo.2012.04.007","article-title":"Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction","volume":"25","author":"Poterucha","year":"2012","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.annonc.2019.10.023_bib101","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1139\/cjpp-2012-0398","article-title":"Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist","volume":"91","author":"Mornos","year":"2013","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.annonc.2019.10.023_bib102","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1067\/mnc.2003.7","article-title":"Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era","volume":"10","author":"Mitani","year":"2003","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib103","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pcad.2010.04.002","article-title":"Role of biomarkers in chemotherapy-induced cardiotoxicity","volume":"53","author":"Cardinale","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.annonc.2019.10.023_bib104","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.hfc.2011.03.002","article-title":"Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy","volume":"7","author":"Ky","year":"2011","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.annonc.2019.10.023_bib105","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.1999.17.7.2237","article-title":"Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin","volume":"17","author":"Herman","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib106","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/annonc\/mdf132","article-title":"Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients","volume":"13","author":"Jensen","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib107","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib108","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0002-9343(87)90212-9","article-title":"Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography","volume":"82","author":"Schwartz","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib109","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/sj.bjc.6600346","article-title":"Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients","volume":"86","author":"Nousiainen","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib110","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.2004.03.516","article-title":"Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial","volume":"22","author":"Perez","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib111","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2007.14.8742","article-title":"Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?","volume":"26","author":"Ewer","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib112","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy","volume":"266","author":"Steinherz","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2019.10.023_bib113","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.amjcard.2006.10.063","article-title":"Acute cardiac functional and morphological changes after anthracycline infusions in children","volume":"99","author":"Ganame","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib114","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib115","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib116","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib117","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib118","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib119","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cardfail.2016.03.016","article-title":"Biomarkers as predictors of cardiac toxicity from targeted cancer therapies","volume":"22","author":"Witteles","year":"2016","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.annonc.2019.10.023_bib120","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib121","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2001.19.10.2587","article-title":"Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification","volume":"19","author":"Seidman","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib122","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib123","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ejca.2004.01.011","article-title":"Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial","volume":"40","author":"Untch","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib124","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib125","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","article-title":"Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience","volume":"24","author":"Guarneri","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib126","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/jnci\/djh253","article-title":"Probabilities of death from breast cancer and other causes among female breast cancer patients","volume":"96","author":"Schairer","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2019.10.023_bib127","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/EDE.0000000000000394","article-title":"Cardiovascular disease mortality among breast cancer survivors","volume":"27","author":"Bradshaw","year":"2016","journal-title":"Epidemiology"},{"key":"10.1016\/j.annonc.2019.10.023_bib128","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2019.10.023_bib129","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","article-title":"Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"163","author":"Steingart","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.annonc.2019.10.023_bib130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1634\/theoncologist.2009-0252","article-title":"Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?","volume":"15","author":"Vaklavas","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2019.10.023_bib131","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2012-0466","article-title":"Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors","volume":"18","author":"Lenihan","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2019.10.023_bib132","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1752-8062.2008.00090.x","article-title":"Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase","volume":"2","author":"Kerkela","year":"2009","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.annonc.2019.10.023_bib133","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/cncr.23460","article-title":"Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor","volume":"112","author":"Khakoo","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib134","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2019.10.023_bib135","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annonc.2019.10.023_bib136","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2019.10.023_bib137","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib138","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jacc.2017.11.005","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib139","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2019.10.023_bib140","doi-asserted-by":"crossref","first-page":"e004408","DOI":"10.1161\/CIRCHEARTFAILURE.117.004408","article-title":"Longitudinal assessment of vascular function with sunitinib in patients with metastatic renal cell carcinoma","volume":"11","author":"Catino","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.annonc.2019.10.023_bib141","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-07-4783","article-title":"Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy","volume":"14","author":"Curwen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2019.10.023_bib142","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib143","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1200\/JCO.2010.34.4309","article-title":"Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib","volume":"29","author":"Richards","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib144","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bcp.12387","article-title":"Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials","volume":"78","author":"Qi","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.annonc.2019.10.023_bib145","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1158\/1078-0432.CCR-16-2869","article-title":"Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma","volume":"23","author":"Narayan","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2019.10.023_bib146","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib147","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib148","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2010.07.023","article-title":"Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?","volume":"56","author":"Yoon","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib149","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cardfail.2013.12.018","article-title":"Cancer therapy-induced left ventricular dysfunction: interventions and prognosis","volume":"20","author":"Thakur","year":"2014","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.annonc.2019.10.023_bib150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1078-0432.CCR-07-1033","article-title":"Cardiac toxicity in breast cancer survivors: review of potential cardiac problems","volume":"14","author":"Bird","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2019.10.023_bib151","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pcad.2010.06.002","article-title":"The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society","volume":"53","author":"Lenihan","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.annonc.2019.10.023_bib152","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","volume":"46","author":"Hunt","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib153","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib154","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.annonc.2019.10.023_bib155","first-page":"296","article-title":"The Canadian Cardiovascular Society Heart Failure Companion: Bridging guidelines to your practice","volume":"32","author":"Howlett","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib156","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cardfail.2016.03.012","article-title":"Cardio-oncology training: A proposal from the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty","volume":"22","author":"Lenihan","year":"2016","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.annonc.2019.10.023_bib157","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib158","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2002.12.102","article-title":"Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer","volume":"20","author":"Lipshultz","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib159","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2004.06.022","article-title":"Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines","volume":"22","author":"Silber","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib160","first-page":"145","article-title":"Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group","volume":"3","author":"Seymour","year":"1999","journal-title":"Cancer Prev Control"},{"key":"10.1016\/j.annonc.2019.10.023_bib161","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib162","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1634\/theoncologist.2015-0125","article-title":"Continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction","volume":"20","author":"Yu","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2019.10.023_bib163","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib164","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib165","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","article-title":"Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy","volume":"15","author":"Swain","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib166","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa035153","article-title":"The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia","volume":"351","author":"Lipshultz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib167","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.annonc.2019.10.023_bib168","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.annonc.2019.10.023_bib169","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.annonc.2019.10.023_bib170","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib171","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","article-title":"Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility","volume":"25","author":"Telli","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib172","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00280-012-2025-5","article-title":"Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis","volume":"71","author":"Qi","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.annonc.2019.10.023_bib173","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bcp.12149","article-title":"Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis","volume":"76","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.annonc.2019.10.023_bib174","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.ejca.2014.05.013","article-title":"Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events","volume":"50","author":"Ewer","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib175","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(16)30573-3","article-title":"Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA","volume":"18","author":"Mayer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib176","first-page":"271","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2019.10.023_bib177","first-page":"831","article-title":"Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy","volume":"32","author":"Virani","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib178","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2015.63.4550","article-title":"CELF4 variant and anthracycline-related cardiomyopathy: A Children's Oncology Group genome-wide association study","volume":"34","author":"Wang","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib179","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/M13-2498","article-title":"Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure","volume":"160","author":"Wong","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib180","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.echo.2013.07.005","article-title":"Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European association of cardiovascular imaging and the american society of echocardiography","volume":"26","author":"Lancellotti","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.annonc.2019.10.023_bib181","doi-asserted-by":"crossref","first-page":"608","DOI":"10.6004\/jnccn.2017.0064","article-title":"Hodgkin lymphoma version 1.2017, NCCN Clinical practice guidelines in oncology","volume":"15","author":"Hoppe","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.annonc.2019.10.023_bib182","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ijrobp.2009.12.054","article-title":"Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease","volume":"79","author":"Machann","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2019.10.023_bib183","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2009.23.2488","article-title":"Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial","volume":"28","author":"Galvao","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib184","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11764-009-0110-5","article-title":"An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis","volume":"4","author":"Speck","year":"2010","journal-title":"J\u00a0Cancer Surviv"},{"key":"10.1016\/j.annonc.2019.10.023_bib185","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1249\/MSS.0b013e3181e0c112","article-title":"American College of Sports Medicine roundtable on exercise guidelines for cancer survivors","volume":"42","author":"Schmitz","year":"2010","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.annonc.2019.10.023_bib186","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1200\/JCO.2006.08.2024","article-title":"Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial","volume":"25","author":"Courneya","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib187","first-page":"243","article-title":"Nutrition and physical activity guidelines for cancer survivors","volume":"62","author":"Rock","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2019.10.023_bib188","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/0284186X.2010.529822","article-title":"Updated evidence in support of diet and exercise interventions in cancer survivors","volume":"50","author":"Pekmezi","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib189","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2002.20.4.1128","article-title":"Weight loss in breast cancer patient management","volume":"20","author":"Chlebowski","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib190","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-0990-0","article-title":"Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis","volume":"123","author":"Protani","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annonc.2019.10.023_bib191","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2009.26.8797","article-title":"Energetics in colorectal and prostate cancer","volume":"28","author":"Meyerhardt","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib192","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cncr.22443","article-title":"Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality","volume":"109","author":"Wright","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib193","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/107327481001700107","article-title":"The effects of obesity and obesity-related conditions on colorectal cancer prognosis","volume":"17","author":"Siegel","year":"2010","journal-title":"Cancer Control"},{"key":"10.1016\/j.annonc.2019.10.023_bib194","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.2005.01.079","article-title":"Weight, weight gain, and survival after breast cancer diagnosis","volume":"23","author":"Kroenke","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib195","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1200\/JCO.2007.15.6687","article-title":"Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803","volume":"26","author":"Meyerhardt","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib196","first-page":"1566","article-title":"Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial","volume":"170","author":"Look","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib197","doi-asserted-by":"crossref","first-page":"9295","DOI":"10.1200\/JCO.2005.02.0198","article-title":"Dietary patterns and survival after breast cancer diagnosis","volume":"23","author":"Kroenke","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib198","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1200\/JCO.2008.19.4035","article-title":"Dietary patterns and breast cancer recurrence and survival among women with early-stage breast cancer","volume":"27","author":"Kwan","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib199","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.298.7.754","article-title":"Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer","volume":"298","author":"Meyerhardt","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2019.10.023_bib200","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib201","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib202","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib203","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.023_bib204","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib205","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1634\/theoncologist.2018-0157","article-title":"Myocarditis associated with immune checkpoint inhibitors: An expert consensus on data gaps and a call to action","volume":"23","author":"Neilan","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2019.10.023_bib206","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.annonc.2019.10.023_bib207","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2019.10.023_bib208","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0140-6736(18)31556-3","article-title":"Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply","volume":"392","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2019.10.023_bib209","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2019.10.023_bib210","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1634\/theoncologist.2019-0040","article-title":"Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: The Memorial Sloan Kettering Cancer Center experience","volume":"24","author":"Lee Chuy","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2019.10.023_bib211","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib212","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","article-title":"A\u00a0clinicopathologic analysis of Adriamycin cardiotoxicity","volume":"32","author":"Lefrak","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2019.10.023_bib213","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-Oncology Services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.annonc.2019.10.023_bib214","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1016\/j.jacc.2018.05.008","article-title":"Cardio-oncology for GenNext: a missing piece of the training puzzle","volume":"71","author":"Ganatra","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annonc.2019.10.023_bib215","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/j.jacc.2019.02.041","article-title":"Preparing the cardiovascular workforce to care for oncology patients: JACC Review Topic of the Week","volume":"73","author":"Hayek","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419360806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419360806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:56:12Z","timestamp":1760334972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419360806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":215,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0923753419360806"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2019.10.023","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2019.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}